|

anti Tim-3/CD123 CAR-T cell therapy Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Xuzhou Medical University1

Indications

  • Acute Myeloid Leukemia, in Relapse1
  • Acute Myeloid Leukemia Refractory1
  • Cancer1

Other1 trial

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.